Application of the complex Edelim in pathogenetic management of patients with erectile dysfunction

Abstract

AIM: To assess the degree of changes in complaints, dynamics of biochemical parameters of lipid metabolism, penile hemodynamics in patients with ED during therapy with EDELIM in comparison with PDE-5 inhibitors. Assess the tolerability of the drug based on the analysis of reported adverse events.

MATERIALS AND METHODS: The study was prospective comparative observational cohort. The study included 60 patients over 18 years old with complaints of persistent, at least 1 month, erectile dysfunction. The patients were divided into 2 groups: group 1 – patients with ED received Edelim on a regular basis, one capsule 2 times daily for 3 months; group 2 – patients with ED received generic tadalafil 5 mg daily for 1 month, then 1 month break, then 5 mg per day for 1 month.

RESULTS: The mean age of the patients was 38.4 ± 9.2 years. In group 1, significant differences were noted in the all hemodynamic and biochemical indicators, except for HDL levels (2.2 ± 0.4 vs. 2.3 ± 0.4 mmol/L; p = 0.067). In group 2, significant differences were noted in the dynamics of the IIEF-5 scale, the level of HDL, and the blood flow velocity in the right and left cavernous arteries. There were no significant differences in blood flow in the left and right dorsal arteries, levels of total cholesterol, LDL, triglycerides, glucose, HbA1c, systolic blood pressure. In the 1st group of patients, there were no adverse events, in the 2nd group, in 3 patients – mild side effects.

CONCLUSIONS: The improvement in the quality of erection in the group of patients taking Edelim is associated with decrease in the lipid profile, glucose, glycated hemoglobin, which can be regarded as a variant of pathogenetic conservative treatment of ED.

Keywords

erectile dysfunction / Edelim / conservative treatment / penile hemodynamics

References

[1] Kaprin AD, Kostin AA, Kruglov DP, et al. Modern methods of instrumental diagnostics of vasculogenic erectile dysfunction. Experimental and Clinical Urology. 2016;(3):102–111. (In Russ.)

[2] Каприн А.Д., Костин А.А., Круглов Д.П., и др. Современные методы инструментальной диагностики васкулогенной эректильной дисфункции // Экспериментальная и клиническая урология. 2016. № 3. С. 102–111.

[3] Mironov SA, Artifeksov SB. Erectile dysfunction. Pathophysiology connection with adjustment disorder (review of the literature, short). Journal of New Medical Technologies. 2013;(1):171. (In Russ.) Avai¬lable from: https://cyberleninka.ru/article/n/erektilnaya-disfunktsiya-patofiziologicheskaya-svyaz-s-rasstroystvami-adaptatsii-obzor-literatury-kratkiy/viewer

[4] Миронов С.А., Артифексов С.Б. Эректильная дисфункция. Патологическая связь с расстройством адаптации (обзор литературы) // Вестник новых медицинских технологий. 2013. № 1. С. 171. Режим доступа: https://cyberleninka.ru/article/n/erektilnaya-disfunktsiya-patofiziologicheskaya-svyaz-s-rasstroystvami-adaptatsii-obzor-literatury-kratkiy/viewer. Дата обращения: 13.09.2021.

[5] Bondarenko NA, Demyanova IO. Social protection of the population and its legal regulation in Russia. Uchenye zametki TOGU. 2017;(1–1):429–433. (In Russ.)

[6] Бондаренко Н.А., Демьянова И.О. Социальная защита населения и ее нормативно-правовое регулирование в РФ // Ученые заметки ТОГУ. 2017. Т. 8, № 1–1. С. 429–433.

[7] Bondarenko VM, Dosta NI, Zhebentyaev AA. Some pathogenetic aspects of erectile dysfunction. Novosti khirurgii. 2015;23(2):217–225. (In Russ.) DOI: 10.18484/2305-0047.2015.2.217

[8] Бондаренко В.М., Доста Н.И., Жебентяев А.А. Патогенетические аспекты эректильной дисфункции // Новости хирургии. 2015. Т. 23, № 2. С. 217–225. DOI: 10.18484/2305-0047.2015.2.217

[9] Popov SV, Orlov IN, Grin’ YeA, et al. Erectile dysfunction: new technologies and approaches in diagnostics and treatment. Vestnik urologii. 2020;8(2):78–92. (In Russ.) DOI: 10.21886/2308-6424-2020-8-2-78-92

[10] Попов С.В., Орлов И.Н., Гринь Е.А., и др. Новые технологии и подходы в диагностике и лечении эректильной дисфункции // Вестник урологии. 2020. Т. 8, № 2. С. 78–92. DOI: 10.21886/2308-6424-2020-8-2-78-92

[11] Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J. 2017;93(1105):679–685. DOI: 10.1136/postgradmedj-2016-134073

[12] Mobley D.F., Khera M., Baum N. Recent advances in the treatment of erectile dysfunction // Postgrad Med J. 2017. Vol. 93, No. 1105. P. 679–685. DOI: 10.1136/postgradmedj-2016-134073

[13] Imprialos KP, Stavropoulos K, Doumas M, et al. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Curr Vasc Pharmacol. 2018;16(2):130–142. DOI: 10.2174/1570161115666170609101502

[14] Imprialos K.P., Stavropoulos K., Doumas M., et al. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy // Curr Vasc Pharmacol. 2018. Vol. 16, No. 2. P. 130–142. DOI: 10.2174/1570161115666170609101502

[15] Chu NV, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep. 2002;2(1):60–66. DOI: 10.1007/s11892-002-0059-5

[16] Chu N.V., Edelman S.V. Erectile dysfunction and diabetes // Curr Diab Rep. 2002. Vol. 2, No. 1. P. 60–66. DOI: 10.1007/s11892-002-0059-5

[17] Gamidov SI, Ovchinnikov RI, Popova AYu. Combined therapy of erectile dysfunction. Effektivnaya farmakoterapiya. 2017;(32):12–20. (In Russ.)

[18] Гамидов С.И., Овчинников Р.И., Попова А.Ю. Комбинированная терапия эректильной дисфункции // Эффективная фармакотерапия. 2017. № 32. С. 12–20.

[19] Azimov SI, Gulamov MKh, Karimov BSU. Complex pathogenetic treatment of patients with diabetes mellitus complicated by erectile dysfunction. Vestnik Nauki i Obrazovaniya. 2020;(23(101)):76–80. (In Russ.)

[20] Азимов С.И., Гуламов М.Х., Каримов Б.С.У. Комплексное патогенетическое лечение больных с сахарным диабетом, осложненным эректильной дисфункцией // Вестник науки и образования. 2020. № 23–101. С. 76–80.

[21] Andersson KE. Pharmacology of erectile function and dysfunction. Urol Clin North Am. 2001;28(2):233–247. DOI: 10.1016/s0094-0143(05)70134-8

[22] Andersson K.E. Pharmacology of erectile function and dysfunction // Urol Clin North Am. 2001. Vol. 28, No. 2. P. 233–247. DOI: 10.1016/s0094-0143(05)70134-8

[23] Aita G, Ros CTD, Lorenzini F, et al. Erectile dysfunction: drug treatment. Rev Assoc Med Bras (1992). 2019;65(9):1133–1142. DOI: 10.1590/1806-9282.65.9.1133

[24] Aita G., Ros C.T.D., Lorenzini F., et al. Erectile dysfunction: drug treatment. Rev Assoc Med Bras (1992). 2019. Vol. 65, No. 9. P. 1133–1142. DOI: 10.1590/1806-9282.65.9.1133

[25] Hsieh CH, Hsu GL, Chang SJ, et al. Surgical niche for the treatment of erectile dysfunction. Int J Urol. 2020;27(2):117–133. DOI: 10.1111/iju.14157

[26] Hsieh C.H., Hsu G.L., Chang S.J., et al. Surgical niche for the treatment of erectile dysfunction // Int J Urol. 2020. Vol. 27, No. 2. P. 117–133. DOI: 10.1111/iju.14157

[27] Munk NE, Knudsen JS, Comerma-Steffensen S, et al. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. Sex Med Rev. 2019;7(3):430–441. DOI: 10.1016/j.sxmr.2018.11.007

[28] Munk N.E., Knudsen J.S., Comerma-Steffensen S., et al. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails // Sex Med Rev. 2019. Vol. 7, No. 3. P. 430–441. DOI: 10.1016/j.sxmr.2018.11.007

[29] Zhebentyaev AA, Goldytskii SO. Sovremennye metody diagnostiki i lecheniya erektil’noi disfunktsii. Surgery News. 2009;17(4): 150–159. (In Russ.)

[30] Жебентяев А.А., Голдыцкий С.О. Современные методы диагностики и лечения эректильной дисфункции // Новости хирургии. 2009. Т. 17, № 4. С. 150–159.

[31] Kyzlasov PS, Bokov AI, Abdulkhamidov AN, et al. Novyi podkhod k revaskulyarizatsii polovogo chlena. In: Proceedings of the V congress of urologists of Siberia with international participation. Topical issues of urology; Krasnoyarsk, 13–14 May 2016. Krasnoyarsk: KASS; 2016. P. 152–154. (In Russ.)

[32] Кызласов П.С., Боков А.И., Абдулхамидов А.Н., и др. Новый подход к реваскуляризации полового члена: Сборник научных трудов V конгресса урологов Сибири с международным участием. Актуальные вопросы урологии. Красноярск, 13–14 мая 2016 г. Красноярск: КАСС, 2016. С. 152–154.

[33] Burdin KA, Kyzlasov Pavel S, Mustafaev AT, et al. Justification of the optimal scheme of shock wave therapy for vasculogenic erectile dysfunction. Experimental and Clinical Urology. 2020;(4):89–95. (In Russ.) DOI: 10.29188/2222-8543-2020-13-4-89-94

[34] Бурдин К.А., Кызласов П.С., Мустафаев А.Т., и др. Обоснование оптимальной схемы ударно-волновой терапии при васкулогенных эректильных дисфункциях // Экспериментальная и клиническая урология. 2020. № 4. С. 89–95. DOI: 10.29188/2222-8543-2020-13-4-89-94

[35] Ivanov VA, Gunov SV. Anatomical aspects of disorder of venous blood outflow from cavity cells and method of its elimination. Integrativnye tendentsii v meditsine i obrazovanii. 2021;2:44–49. (In Russ.)

[36] Иванов В.А., Гунов С.В. Анатомические аспекты нарушения оттока венозной крови от клеток пещеристых тел и метод его устранения // Интегративные тенденции в медицине и образовании. 2021. Т. 2. С. 44–49.

[37] Doppalapudi SK, Wajswol E, Shukla PA, et al. Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies. J Vasc Interv Radiol. 2019;30(8):1251–1258. DOI: 10.1016/j.jvir.2019.01.024

[38] Doppalapudi S.K., Wajswol E., Shukla P.A., et al. Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies // J Vasc Interv Radiol. 2019. Vol. 30, No. 8. P. 1251–1258. DOI: 10.1016/j.jvir.2019.01.024

[39] Kurbatov DG, Kuznetsky YuYa, Petritschko MI, et al. Conservative treatment of erectile dysfunction in men with age-related androgen deficiency. Vestnik Meditsinskogo stomatologicheskogo instituta. 2017;(2):24–31. (In Russ.)

[40] Курбатов Д.Г., Кузнецкий Ю.Я., Петричко М.И., и др. Консервативное лечение эректильной дисфункции у мужчин с возрастным андрогенодефицитом // Вестник Медицинского стоматологического института. 2017. № 2. С. 24–31.

[41] Bakr AM, El-Sakka AA, El-Sakka AI. Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2021;22(7):821–834. DOI: 10.1080/14656566.2020.1851365

[42] Bakr A.M., El-Sakka A.A., El-Sakka A.I. Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction // Expert Opin Pharmacother. 2021. Vol. 22, No. 7. P. 821–834. DOI: 10.1080/14656566.2020.1851365

RIGHTS & PERMISSIONS

Eco-Vector